Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of DNOW Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased DNOW securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Financial Performance and Market Reaction - DNOW shares experienced a significant decline of 19.1% on February 20, 2026, following the release of disappointing fourth-quarter 2025 financial results, which included a substantial loss and missed Wall Street expectations [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alight, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Alight securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Alight [2]. Group 2: Financial Performance - On February 19, 2026, Alight reported a gross profit of $240 million and a gross profit margin of 36.8%, down from $271 million and 39.9% in the prior year [3]. - The adjusted gross profit was reported at $272 million with an adjusted gross profit margin of 41.7%, compared to $300 million and 44.1% in the previous year [3]. - Following the release of these results, Alight's stock experienced a significant decline of 38.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors, including over $438 million in 2019 [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and recognition in the field [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Vital Farms, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders of Vital Farms who purchased securities may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - Investors interested in joining the class action can submit their information through the provided link or contact the firm directly [2]. Group 2: Stock Performance and Earnings - On February 26, 2026, Vital Farms' stock price experienced a significant decline of 10.8% following the announcement of weaker than expected quarterly earnings, as reported by MarketBeat [3].

Core Viewpoint - Rosen Law Firm is reminding sellers of Masonite International Corporation common stock about a class action lawsuit with a lead plaintiff deadline of April 7, 2026 [1]. Group 1: Class Action Details - Sellers of Masonite common stock between June 5, 2023, and February 8, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise [4]. Group 3: Case Specifics - The lawsuit alleges that during the class period, defendants made material omissions and misrepresentations regarding Owens Corning's offers to purchase Masonite's stock at significant premiums, which could have indicated a higher value for Masonite's stock if disclosed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is claimed that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5].

New York, New York--(Newsfile Corp. - March 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT ...

Group 1 - The Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ: MREO) about the April 6, 2026 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Mereo ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][7] Group 2 - The lawsuit alleges that Mereo BioPharma provided misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5] - Defendants reportedly made positive statements about setrusumab's potential to reduce annualized fracture rates while concealing adverse facts about the studies not meeting their primary endpoints [6] - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information was revealed [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Oracle Corporation common stock between June 12, 2025, and December 16, 2025, of the April 6, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Oracle stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 6, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that Oracle made false or misleading statements regarding its AI infrastructure strategy, which led to increased capital expenditures without corresponding revenue growth [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit claims that Oracle's increased spending posed risks to its debt, credit rating, and free cash flow, which were not disclosed to investors [4]. - It is asserted that the defendants' statements about Oracle's business and prospects were materially false and misleading, leading to investor damages when the truth was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta, claiming confidence in the drug's efficacy while concealing material adverse facts [5][6]. - It is claimed that the positive statements made by the defendants led to investors purchasing Ultragenyx securities at artificially inflated prices, resulting in damages when the true information was revealed [6].

Group 1 - The Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ: MREO) about the April 6, 2026 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Mereo ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][7] Group 2 - The lawsuit alleges that Mereo BioPharma provided misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5] - Defendants are accused of making positive statements about setrusumab's efficacy while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6] - The misleading statements led to investors purchasing Mereo's ADSs at inflated prices, resulting in damages when the true information became public [6]